1022931-81-2

Usage

Structure

Pyrrolidine derivative with a carbonyl group attached to a pyrrolidine ring and a 4-bromo-3-fluorophenyl substituent

Potential applications

Medicinal chemistry and drug development due to its unique structure and potential biological activities

Further research needed

To determine specific pharmacological properties and potential therapeutic uses

Use as a chemical reagent

In organic synthesis and chemical reactions to introduce the pyrrolidine moiety into other molecules and create new compounds with diverse properties

Significance

Potential importance in both the pharmaceutical and chemical industries

Further investigation

Required to explore its potential applications and uses

Upstream product

• 123-75-1 pyrrolidine 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 

Downstream Products

• 1057662-49-3 1-[2-fluoro-4-(1-pyrrolidinylcarbonyl)phenyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole 
• 1022930-95-5 1-[2-fluoro-4-(1-pyrrolidinylcarbonyl)phenyl]-3-(trifluoromethyl)-1,4,6,7-tetrahydropyrano[4,3-c]pyrazole 
• 874289-25-5 C₁₁H₁₃BFNO₃ 
• 1264616-14-9 C₁₇H₂₃BFNO₃ 
• 1264616-07-0 C₁₇H₂₅BFNO₃ 
• 1264616-09-2 C₂₃H₃₈B₂FNO₅ 

Relevant academic research and scientific papers

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

A robust three-step telescoped synthesis of electron-deficient amide substituted arylboronic acids

A robust three-step telescoped process for the preparation of electron-deficient amide-substituted arylboronic acids from readily available bromobenzoic acids has been developed. An EDC-HOBT-promoted amide formation of a bromobenzoic acid was followed by subjection of the product stream to a palladium-mediated cross-coupling with B2(pin)2. The resultant mixture of the arylboronate ester and arylboronic acid was directly treated with NaIO4, followed by a heptane-MeTHF crystallization, to cleanly afford the corresponding arylboronic acid in good yield. This general procedure was used to synthesize electron-deficient amide-substituted arylboronic acids with a diverse array of electron-withdrawing substituents.

COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE

Compounds of formula (I), and salts and solvates thereof are provided: Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.

COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE

A compound of formula (I) and salts thereof are provided: wherein A is defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.